From Name:
From Email:
To Name:
To Email:

Optional Message:

FDA approves ER hydrocodone with abuse deterrence technology

from Pharmacy Practice News

The FDA has approved Vantrela extended-release tablets with Teva’s proprietary abuse deterrence technology targeting oral, intranasal and IV routes. Vantrela ER is indicated to manage pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063